Want to see GENB full AI Analyst Report?
GENB Stock Chart & Stats
$15.33
--
Market closed
$15.33
--
Day’s Range― - ―
52-Week Range$11.00 - $22.67
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.20M
Market Cap
$2.08B
Enterprise Value$1.77K
Total Cash (Recent Filing)$457.42M
Total Debt (Recent Filing)$62.63M
Price to Earnings (P/E)―
Beta0.53
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding128,352,430
10 Day Avg. Volume906,803
30 Day Avg. Volume1,199,819
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-1.03
Price to Sales (P/S)19.87
P/FCF Ratio-3.10
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$26.50Price Target Upside72.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthTop-line growth indicates increasing commercial traction for the company’s platform and collaboration activities. Sustained revenue expansion could improve operating leverage over time, although the current scale remains insufficient to offset substantial research and development costs.
AI Protein-Design PlatformThe generative protein-design platform may provide a repeatable technology base across multiple disease areas, potentially improving discovery efficiency and creating opportunities for internally developed assets and research partnerships as programs mature.
Debt ReductionLower absolute debt modestly reduces fixed financial obligations and may provide some balance-sheet relief. This is a constructive element of capital structure management, although it does not offset the company’s deeply negative equity position and ongoing cash requirements.
Bears Say
Widening Net LossesLosses are increasing despite revenue growth, showing that operating expenses continue to overwhelm the company’s current revenue base. Persistent, deeply negative margins could require prolonged external funding and delay the path to sustainable profitability.
Accelerating Cash BurnCash outflows are worsening and closely track reported losses, indicating that the deficit is converting into real funding needs rather than being mainly non-cash. Continued burn raises dilution, financing, and execution risks if partners or capital markets do not provide support.
Negative Equity And Shrinking AssetsDeeply negative equity and materially lower assets weaken financial flexibility and reduce the balance-sheet cushion available to absorb development setbacks. This structure can make future financing more difficult and increases dependence on successful programs or new funding.
GENB FAQ
What was Generate Biomedicines, Inc.’s price range in the past 12 months?
Generate Biomedicines, Inc. lowest stock price was $11.00 and its highest was $22.67 in the past 12 months.
What is Generate Biomedicines, Inc.’s market cap?
Generate Biomedicines, Inc.’s market cap is $2.08B.
When is Generate Biomedicines, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Generate Biomedicines, Inc.’s earnings last quarter?
Currently, no data Available
Is Generate Biomedicines, Inc. overvalued?
According to Wall Street analysts Generate Biomedicines, Inc.’s price is currently Undervalued.
Does Generate Biomedicines, Inc. pay dividends?
Generate Biomedicines, Inc. does not currently pay dividends.
What is Generate Biomedicines, Inc.’s EPS estimate?
Generate Biomedicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Generate Biomedicines, Inc. have?
Generate Biomedicines, Inc. has 128,352,430 shares outstanding.
What happened to Generate Biomedicines, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Generate Biomedicines, Inc.?
Currently, no hedge funds are holding shares in GENB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Generate Biomedicines, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.50 (72.86% Upside)
$26.50 (72.86% Upside)
Blogger Sentiment
Bullish
GENB Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 786.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 24.9%
Last 30 Days ▲ 24.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Learn more about TipRanks Smart Score
Company Description
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
GENB Stock 12 Month Forecast
Average Price Target
$26.50
▲(72.86% Upside)
Technical Analysis
Zymeworks
―
AbCellera Biologics
―
Recursion Pharmaceuticals
―
AbSci
―
Eikon Therapeutics, Inc.
―
Ownership Overview
52.01% Insiders
<0.01% Mutual Funds
5.19% Other Institutional Investors
39.78% Public Companies and
Individual Investors